Cognitive function
AssigneeMars, Incorporated
InventorHelmut Sies
Life of this patent
Estimating the term…
Abstract
This invention relates to compositions containing polyphenols, for example, cocoa polyphenols such as flavanols and their related oligomers, and methods for treating abnormalities in gap junctional communication of cells, such as cancer, heart arrhythmia, neuro-degenerative diseases and cognitive dysfunction.
Claims51
A method of treating a subject suffering from cognitive dysfunction comprising administrating to the subject a composition in a unit dosage form comprising an effective amount of at least 50 mg of at least one compound having the formula An, a pharmaceutically acceptable salt thereof, and any mixture thereof:
- wherein
- A is epicatechin;
- n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
- bonding between adjacent monomeric units takes place at positions selected from the group consisting of 4, 6 and 8;
- a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
- X, Y and Z are selected from the group consisting of monomeric unit A and hydrogen, with the proviso that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
- wherein the subject is a human or a veterinary animal, and wherein the composition comprises at least 50 mg of the at least one compound per unit dose.
A method of treating a human subject suffering from cognitive dysfunction comprising administrating to the subject a composition in unit dosage form comprising an effective amount of a cocoa extract comprising at least 50 mg of at least one compound having the formula An
- wherein
- A is epicatechin;
- n is an integer from 2 to 10, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
- bonding between adjacent monomeric units takes place at positions selected from the group consisting of 4, 6 and 8;
- a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
- X, Y and Z are selected from the group consisting of monomeric unit A and hydrogen, with the proviso that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
- wherein the composition comprises at least 50 mg of the at least one compound per unit dose.
A method of improving cognitive function in a subject suffering from a neurodegenerative disease comprising administrating to the subject, as a regimen, a composition in unit dosage form comprising an effective amount of at least 50 mg of a of at least one compound having the formula An, a pharmaceutically acceptable salt thereof, and any mixture thereof:
- wherein
- A is epicatechin;
- n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
- bonding between adjacent monomeric units takes place at positions selected from the group consisting of 4, 6 and 8;
- a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
- X, Y and Z are selected from the group consisting of monomeric unit A and hydrogen, with the proviso that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
- and
- wherein the subject is a human or a veterinary animal, and wherein the composition comprises at least 50 mg of the at least one compound per unit dose.
A method of improving cognitive function in a human subject suffering from a neurodegenerative disease comprising administrating to the subject, as a regimen, a composition in unit dosage form comprising an effective amount of a cocoa extract comprising at least 50 mg of at least one compound having the formula An:
- wherein
- A is epicatechin;
- n is an integer from 2 to 10, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
- bonding between adjacent monomeric units takes place at positions selected from the group consisting of 4, 6 and 8;
- a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
- X, Y and Z are selected from the group consisting of monomeric unit A and hydrogen, with the proviso that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen, wherein the composition comprises at least 50 mg of the at least one compound per unit dose.
Dependencies are inferred from the claim text.